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Abstract
Background: About one third of patients infected with human immunodeficiency virus (HIV) also have chronic
hepatitis due to hepatitis C virus (HCV). HCV therapy with simeprevir, pegylated interferon alfa (PegIFNα) and
ribavirin (RBV) have been shown to be superior to PegIFNα + RBV alone in non-HIV patients, but no randomized
trials in patients with HCV genotype 1 (HCV-1) / HIV coinfection are available.
Methods: This was a historical comparison of study C212 (simeprevir + PegIFNα-2a + RBV in patients with HCV-1/
HIV coinfection) with studies in which HCV-1/HIV coinfected patients were treated with PegIFNα-2a + RBV alone. A
systematic literature search was performed to identify eligible studies. Efficacy and safety results of PegIFNα-2a +
RBV studies were combined in random- and fixed-effects inverse-variance weighted meta-analyses of proportions
using the Freeman-Tukey double arcsin transformation method, and compared with the results of study C212.
Results: The literature search revealed a total of 2392 records, with 206 articles selected for full-text review. Finally, 11
relevant articles reporting on 12 relevant study groups were included. Results on sustained virologic response
24 weeks after end of treatment (SVR24) were available from all 12 study groups. Pooled SVR24 for PegIFNα-
2a + RBV from the random-effects meta-analysis was 28.2 % (95 % CI 23.8 % to 32.9 %). The comparison
between study C212 (SVR24 = 72.6 %; 95 % CI 63.1 % to 80.9 %) revealed substantial superiority of simeprevir +
PegIFNα-2a + RBV compared to PegIFNα-2a + RBV alone, with an absolute risk difference of 45 % (95 % CI 34 to 55).
This finding was robust in a sensitivity analysis that only included historical studies with a planned treatment duration
of at least 48 weeks and the same RBV dose as in study C212. No increases in the frequency of important adverse
event categories including anemia were identified, but these analyses were limited by the low number of studies.
Conclusion: This historical comparison provides first systematic evidence for the superiority of simeprevir + PegIFNα-
2a + RBV compared to PegIFNα-2a + RBV in patients with HCV-1 / HIV coinfection. Given the limitations of the historical
comparison for safety endpoints, additional data on the comparative safety of simeprevir in patients with HCV-1 / HIV
coinfection would be desirable.
Trial registration: Identifier for study TMC435-TiDP16-C212 (ClinicalTrials.gov): NCT01479868.
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Background
Chronic hepatitis due to hepatitis C virus (HCV) is an im-
portant comorbidity in people infected with the human
immunodeficiency virus (HIV). It has been estimated in
US [1] and European [2] studies that approximately one
third of patients with HIV are coinfected with HCV. The
course of chronic hepatitis due to HCV has been reported
to be more severe in people with HIV, leading to an in-
creased risk of decompensated liver disease, histological
cirrhosis [3, 4] and death [4]. The increased duration of
survival in people with HIV due to the efficacy of highly
active antiretroviral therapy (HAART) has additionally
augmented the importance of successful HCV treatment.
A combination therapy of pegylated interferon alfa
(PegIFNα) plus ribavirin (RBV) has been the cornerstone
of HCV treatment for several years. During the last years,
several new direct acting antivirals have been developed
or are currently in phase II or phase III studies. Three
NS3/4A serine protease inhibitors (boceprevir, telaprevir
and simeprevir) have been licensed for the treatment of
HCV genotype 1 (HCV-1) infection in combination with
PegIFNα + RBV. In individuals without HIV infection,
adding these drugs to PegIFNα + RBV has substantially in-
creased HCV eradication, measured by sustained virologic
response (SVR = undetectable HCV RNA 12 (SVR12) or
24 (SVR24) weeks after completion of treatment) [5]. One
randomized controlled trial (RCT) evaluating the efficacy
and safety of these drugs in patients with HCV-1/HIV co-
infection is available for boceprevir [6] and telaprevir [7],
respectively. However, for simeprevir which has been re-
ported to have advantages over boceprevir and telaprevir
in terms of pill-burden and adverse event (AE) profile,
only a single-arm trial (study identifier TMC435-TiDP16-
C212 = „study C212“) is available [8]. A systematic
comparison between simeprevir + PegIFNα-2a + RBV vs.
PegIFNα-2a + RBV alone in patients with HCV-1/HIV co-
infection is, however, lacking. Aim of this study was to
compare the main results from study C212 (simeprevir +
PegIFNα-2a + RBV) with data from earlier (historical)
studies that evaluated the efficacy and safety of PegIFNα-
2a + RBV in patients with HCV-1/HIV coinfection. Focus
of this comparison was SVR, in addition data on import-
ant AE categories (e.g. total AEs; total SAEs; total AEs




This is a historical comparison (also called non-adjusted
indirect comparison) which compares study C212 (sime-
previr + PegIFNα-2a + RBV in patients with chronic HCV-
1/HIV coinfection) with studies and/or study groups in
which HCV-1/HIV coinfected patients were treated with
PegIFNα-2a + RBV only. The conduct of the historical
comparison consisted of the following steps: 1) a system-
atic literature search and selection of relevant studies; 2) a
meta-analysis of proportions; 3) a re-transformation of the
meta-analysis results (i.e. proportions and 95 % confidence
intervals (CI)) into corresponding numerator / denomin-
ator pairs; and 4) a historical comparison of the results
from study C212 with historical results from the meta-
analysis. The systematic review and meta-analysis was
performed and reported in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA)-Statement [9].
Eligibility criteria
To increase the validity of the historical comparison inclu-
sion and exclusion criteria were aligned to the study de-
sign of C212. Study C212 (ClinicalTrials.gov identifier
NCT01479868) is an open-label, single arm clinical study
to evaluate the safety, tolerability and efficacy of simepre-
vir along with PegIFNα-2a and RBV triple therapy in adult
chronic HCV genotype-1 infected patients who were coin-
fected with the human immunodeficiency virus-type 1
(HIV-1). The study included HCV treatment-naïve pa-
tients who never received medication for the treatment of
HCV, as well as relapsers and non-responders to prior
HCV therapy . All patients received Simeprevir 150 mg
q.d. for 12 weeks, in combination with PegIFNα-2a
(180 μg per week) and RBV (1000 mg b.i.d. for patients
with a body weight <75 kg; and 1200 mg b.i.d. for patients
with a body weight ≥75 kg). The duration of therapy with
PegIFNα-2a and RBV was 24 or 48 weeks, depending on
virologic response: A shortened duration of 24 weeks was
used for treatment-naïve patients or relapsers who had a
HCV-RNA <25 IU/mL at week 4 (detectable or non-
detectable) and at week 12 (non-detectable); all other
patients received 48 weeks of treatment.
To be included in the meta-analysis studies had to fulfill
all of the following inclusion criteria: 1) Adult patients
with chronic HCV genotype-1 and HIV coinfection. Stud-
ies with patients who had chronic hepatitis C due to other
HCV genotypes were only included, if the publication in-
cluded HCV-1 stratified results for at least one of the end-
points of interest. 2) Treatment with PegIFNα-2a and
RBV for at least 12 weeks (for safety endpoint) or 24 weeks
(for SVR). Studies involving PegIFNα-2b were excluded
due to potential pharmacodynamics differences between
PegIFNα-2a and PegIFNα-2b. 3) Results are presented for
at least one of the pre-defined endpoints of interest: Pro-
portion of patients with SVR 12 or 24 weeks after end of
therapy; proportion of patients with at least one AE;
proportion of patients with at least one serious AE;
proportion of patients who interrupted treatment due
to an AE; proportion of patients with AEs of special
interest (i.e. anemia; psychiatric disorders; infections;
increase of blood bilirubin levels; adverse cutaneous
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events). 4) Study was a RCT or another (e.g. single-arm)
clinical trial, or an observational cohort study. 5) Study re-
sults were available from a full publication in a scientific
journal or a study report (i.e. meeting abstracts and/or
scientific poster presentations were not included). Studies
were excluded, if the population was highly selected (e.g.
selected by previous response/non-response to PegIFNα
and/or RBV; selected by comorbidity such as hemophilia;
selected by concomitant treatment such as a specific HIV
therapy) or if the publication presented a case series or a
study with a very low number of participants (i.e. N < 10
patients in the relevant analyses). For studies with more
than one study arm (e.g. RCTs), the inclusion of two or
more study groups were possible as long as they fulfilled
the eligibility criteria.
Systematic literature search and data extraction
The systematic search for relevant publications were
performed at July 24, 2014, using the electronic data-
bases Medline, EMBASE (Excerpta Medica Database)
and the Cochrane Central Register of Controlled Trials.
The search included terms for HCV and HIV, in com-
bination with intervention terms for PegIFNα-2a and
RBV. The search was limited “human” and to English or
German language. The full electronic search strategy for
Medline is included in an online appendix as an example
(Additional file 1 - electronic search strategy for Medline).
Selection of relevant studies or study groups were per-
formed independently by two authors; potential discrep-
ancies were resolved by discussion. For all included
studies, pre-defined study design characteristics; charac-
teristics of the study populations; and results of the studies
(for relevant endpoints) were extracted.
Statistical analysis
As all endpoints of interest were proportions (i.e. num-
ber of patients with a certain event divided by the total
number of patients), an inverse-variance weighted meta-
analysis of proportions using the Freeman-Tukey double
arcsin transformation method [10, 11] was performed
for each endpoint of interest. Both fixed- and random-
effects meta-analyses were performed and heterogeneity
was evaluated based on Cochran’s Q; I2; and the test for
heterogeneity. To allow a direct comparison with study
C212, the meta-analytical proportions including their
95 % CI were re-transformed into the best-fitting corre-
sponding numerator/denominator pair using iteration.
The iteration identified the numerator/denominator pair
for which the width of the 95 % binomial (Wilson score)
CI is most similar to the width of the meta-analytical
95 % CI. For example, for a meta-analytical proportion
of 0.277 with a 95 % CI of 0.253 to 0.302, the best-fit nu-
merator/denominator pair is 364/1313 (as it corresponds
to a proportion of 0.277 with a 95 % Wilson CI of 0.253
to 0.302). Using these numerator/denominator pairs, rela-
tive risks as well as absolute risk differences of simeprevir +
PegIFNα-2a + RBV (from study C212) vs. PegIFNα-2a +
RBV (from the meta-analyses) were calculated for all end-
points of interest. If for an endpoint results from not more
than one historical study were available, no meta-analysis
was performed for that endpoint and the numerator/de-
nominator pair from the single historical study was used
for the comparison. To evaluate the potential impact of the
duration of treatment and the daily dose of RBV on SVR24,
a pre-planned sensitivity analysis was performed. This ana-
lysis included only studies with a treatment duration of
48 weeks for PegIFNα-2a + RBV and that used RBV in the
same weight-based daily dose as in study C212. To allow a
full evaluation of the available evidence a historical com-
parison of study C212 and each of the identified studies /
study arms was performed in addition to the comparison
with the results from meta analyses. All analyses were per-
formed with SAS 9.3 (SAS Institute, Cary NC).
Results
Literature search
The literature search in Medline, EMBASE, and the
Cochrane Central Register of Controlled Trials revealed a
total of 2392 records. After exclusion of 554 duplicates, a
total of 1838 records remained for review. N = 1632 re-
cords were excluded based on title and/or abstract, leaving
206 articles for full-text review. From these publications,
N = 195 articles were excluded while 11 relevant articles
[12–22] were included (see Fig. 1 for details on the litera-
ture selection process). One of the 11 studies reported on
two relevant study groups, while 10 had one relevant
study arm, resulting in a total of 12 relevant study groups.
Characteristics of included studies
The comparability between the included studies and
study C212 with respect to important characteristics of
study design and patient population was acceptable (see
Table 1 for details). Differences were noted for the dur-
ation of treatment with PegIFNα-2a + RBV; the daily
dose of RBV; and the inclusion/exclusion of relapsers
and/or non-responders to previous PegIFNα-based HCV
therapy. For the following endpoints of interest, results
from at least one of the identified historical studies were
available: Proportion of patients with SVR after 24 weeks
(N = 12 study groups); proportion of patients with at
least one AE (N = 2 study groups); proportion of patients
with at least one serious AE (N = 2 study groups); pro-
portion of patients who interrupted treatment due to an
AE (N = 1 study group); proportion of patients with
anemia (N = 3 study groups); and proportion of patients
with psychiatric disorders (N = 1 study group). No his-
torical comparisons were possible for SVR after 12 weeks
and for the AE categories infections; increase of blood
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bilirubin levels; and adverse cutaneous events. All in-
cluded historical studies reported on SVR24, while only
a minor proportion reported on AEs. This was due to
the fact that only results for patients with HCV-1 infec-
tion were of relevance for the historical comparison.
Publications on studies that also included patients in-
fected with other HCV genotypes, however, reported
HCV-1 stratified results only for SVR but not for AEs.
Historical comparison – efficacy
From all included 12 study groups, results on SVR24
were available. The meta-analysis indicated heterogen-
eity between PegIFNα-2a + RBV study groups (I2 =
65.3 %; p < 0.001). However, the results of the fixed-
effects model (SVR24 = 27.7 %; 95 % CI 25.3 to
30.2 %) and the random-effects model (SVR24 =
28.2 %; 95 % CI 23.8 % to 32.9 % - see Fig. 2) were
similar. After re-transformation of proportions into
estimated numerator/denominator pairs (364/1313 for
the fixed effects model, and 104/369 for the random
effects model; see Additional file 2 for details), the
comparison between study C212 (SVR24 = 72.6 %;
95 % CI 63.1 % to 80.9 %) and the meta-analyses re-
sults revealed substantial superiority of simeprevir +
PegIFNα-2a + RBV compared to PegIFNα-2a + RBV
alone (see Table 2), with a relative risk of 2.58
Fig. 1 Flow chart of literature selection
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Yes Single-arm yes 85 % Treatment-naïve patients +
relapsers with EVR at week 4/12:
24 weeks
1000 mg / 1200 mg
(w.a.)
N = 106 47 years 85 % 13 %





US Yes RCT (not
blinded)
no 82 % Patients without response in
week 24: 24 weeks
600 mg (week 1–4); 800
mg (week 5–8); 1000 mg
(week >8)
N = 51 45 years 82 % 10 %




n.r. Brazil No Single-arm n.r. 88 % 48 weeks 11 mg/kg body
weight





Spain Yes RCT (not
blinded)
no 75 % Patients with EVR in week 12:
48 weeks
800 mg N = 51 39 years 75 % 39 %b
Patients without EVR in week




n.r. Austria Yes Single-arm no 73 % Patients with RVR in week 4:
48 weeks
1000 mg to 1200
mg for 12 weeks; 800 mg
thereafter
N = 28 37 years 73 % 42 %






US No RCT (not
blinded)
n.r. 90 % 48 weeks 1000 mg / 1200 mg
(w.a.)








no 78 % Patients without EVR in week
12: 12 weeks
1000 mg / 1200 mg
(w.a.)
N = 191 39 years 77 % 11 %
Patients with detectable HCV
in week 24: 24 weeks
All other patients: 48 weeks




n.r. Spain Yes Non-
randomized
study
no 92 % Treatment according to 2009
AASLD guidelines (48 weeks;
patients with delayed virologic
response: 72 weeks)
1000 mg / 1200 mg
(w.a.)





























Table 1 Characteristics of included studies (Continued)
Treatment group 2:












no 85 % 48 weeks 1000 mg / 1200 mg
(w.a.)

















n.r. n.r. 48 weeks 1000 mg / 1200 mg
(w.a.)
N = 55 40 years 67 % n.r.
aOnly patients with HCV-1 infection
bBridging fibrosis or fibrosis
cFibrosis stage F3 or F4
dNo early stopping rules according to study protocol, but within the discretion of the study physician














(random effects model) or 2.62 (fixed effects model)
and a risk difference of 45 % (both models).
The sensitivity analysis that included only studies (N = 5)
with at least 48 weeks of treatment duration and weight-
adapted dosing of RBV revealed similar results (random ef-
fects model: RR = 2.59; 95 % CI 2.06 to 3.26 and fixed ef-
fects model: RR = 2.70; 95 % CI 2.28 to 3.21). A direct
comparison between C212 and the individual historical
study groups also showed statistically significant superiority
of simeprevir + PegIFNα-2a + RBV for 11 comparisons; for
one study [15] the effect estimate was not statistically sig-
nificant, but this was attributable to the low number of pa-
tients included in this study (N = 10).
Historical comparison – safety
The comparison between simeprevir + PegIFNα-2a +
RBV and historical data for PegIFNα-2a + RBV did not
indicate an increase in risk of the AE categories included
Table 2 Main results of historical comparison (simeprevir + PegIFNα-2a + RBV vs. PegIFNα-2a + RBV)
Number of patients with event/total number of patients (%) Relative risk
(95 % CI)
Risk difference
(95 % CI)Simeprevir + PegIFNα-2a + RBV PegIFNα-2a + RBV
Efficacy
SVR24 (random effects) 77/106 (72.6 %) 104/369 (28.2 %) 2.58 (2.11; 3.15) 0.45 (0.34; 0.55)
SVR24 (fixed effects) 364/1313 (27.7 %) 2.62 (2.27; 3.03) 0.45 (0.36; 0.54)
Safety
At least one AEa 103/106 (97.2 %) 396/410 (96.6 %) 1.01 (0.97; 1.04) 0.01 (−0.04; 0.05)
At least one SAEa 11/106 (10.4 %) 67/407 (16.5 %) 0.63 (0.35; 1.15) −0.06 (−0.14; 0.01)
AEs leading to discontinuationb 5/106 (4.7 %) 21/135 (15.6 %) 0.30 (0.12; 0.78) −0.11 (−0.19; −0.03)
Anemia AEs (random effects) 35/106 (33.0 %) 58/202 (28.7 %) 1.15 (0.81; 1.63) 0.04 (−0.07; 0.16)
Anemia AEs (fixed effects) 124/418 (29.7 %) 1.11 (0.82; 1.52) 0.03 (−0.07; 0.14)
Psychiatric disorders AEsc 63/106 (59.4 %) 3/10 (30.0 %) 1.98 (0.76; 5.17) 0.29 (−0.06; 0.65)
aNo difference between random and fixed effects models
bResults for PegIFNα-2a + RBV from Torres-Cornejo 2014 [18]
cResults for PegIFNα-2a + RBV from Murphy 2011 [15]
CI confidence interval, SVR24 sustained virologic response 24 weeks after planned end of treatment, AE adverse event, SAE serious adverse event, RBV ribavirin,
PegIFNα-2a peginterferon-alpha-2a
Fig. 2 Sustained virologic response in HCV-1/HIV coinfected patients treated with simeprevir + PegIFNα-2a + RBV (study C212) or PegIFNα-2a +
RBV alone (random-effects meta-analysis of historical studies). CI = confidence interval; RBV = Ribavirin; SVR24 = sustained virologic response
24 weeks after planned end of treatment; w.a. = weight-adapted
Andersohn et al. BMC Infectious Diseases  (2016) 16:10 Page 7 of 11
(see Table 2). These analyses were limited by the low
number of historical studies contributing data.
Discussion
The historical comparison revealed a substantially higher
proportion of patients with SVR with simeprevir +
PegIFNα-2a + RBV compared to PegIFNα-2a + RBV alone
in patients with HCV-1 and HIV coinfection. The absolute
difference in risk was approximately 45 %, which corre-
sponds to a number-needed-to treat of 2.2. No increases
in risk were observed for the total number of AEs; serious
AEs; AEs leading to discontinuation; anemia AEs; or AEs
indicating psychiatric disorders.
For patients with chronic hepatitis due to HCV-1
infection but without HIV, results from RCTs comparing
simeprevir with placebo in addition to PegIFNα + RBV
are available. These trials demonstrated increased SVR
with simeprevir, with absolute differences in risk ranging
between approx. 30 % for treatment-naïve patients
(QUEST-1 [23] and QUEST-2 [24]) and approx. 45 % for
relapsers (PROMISE [25]) or non-responders (ASPIRE
[26]) after a previous IFN-based therapy. These differences
were primarily due to different proportions of patients
with SVR in the placebo groups (i.e. Placebo + PegIFNα +
RBV) of these trials. While treatment-naïve patients
(QUEST-1 and QUEST-2) had a SVR of approx. 50 %,
relapsers (PROMISE) showed a SVR of 36 %, and previous
non-responders had a SVR of 23 %. In the meta-analysis
for the historical comparison, the overall estimate for
PegIFNα-2a + RBV in was 28.2 %, even though included
trials only included treatment-naïve patients or did not
report on prior treatment status. This is in line with the
fact that response to PegIFNα-2a + RBV is worse in
patients with HCV/HIV coinfection, compared to HCV
infection alone [27].
A recent systematic review of the treatment of hepa-
titis C [27] identified two RCTs that compared bocepre-
vir or telaprevir with placebo (in addition to PegIFNα +
RBV) in patients with chronic hepatitis C who were
coinfected with HCV and HIV. The study on boceprevir
[6] included 99 treatment-naïve patients with HCV
genotype 1 infection and a controlled HIV infection and
randomized them 2:1 to boceprevir + PegIFNα-2b + RBV,
or to placebo + PegIFNα-2b + RBV. Boceprevir was su-
perior to placebo with respect to SVR24 (absolute differ-
ence in risk 33.1 %; 95 % CI 13.7-52.5) but was
associated with an increased frequency of AEs such as
anemia. Treatment discontinuations due to AEs oc-
curred more frequently with boceprevir than with pla-
cebo (20 % vs. 9 %). The proportion of patients with
SVR24 in the placebo group (29.4 %) was similar to the
proportion of patients with SVR24 in the meta-analysis
for the historical comparison (28.2 %). The telaprevir
RCT [7] randomized 64 treatment-naïve patients with
HCV genotype 1 infection and HIV-1 infection to tela-
previr or placebo, both in addition to PegIFNα-2a +
RBV. Telaprevir was superior to placebo with respect to
SVR24, with an absolute difference in risk of 29 % (95 %
CI 3–53). The proportion of patients with SVR24 in the
placebo group was 45 % (10 out of 22 patients), however
this estimate was limited by the rather low number of
patients included. Telaprevir was associated with a sig-
nificantly increased frequency of pruritus (39 % vs. 9 %),
and a non-significant increase in the proportion of pa-
tients with at least one serious AE (18 % vs. 9 %).
Compared to simeprevir (1 capsule per day), the pill-
burden associated with boceprevir or telaprevir is sub-
stantially higher (12 capsules or 6 tablets per day, re-
spectively). In addition, simeprevir seems to have some
advantages related to AEs. The frequency of anemia was
similar in the simeprevir and the placebo group in four
RCTs that included non-HIV patients [23–26]. The
historical comparison also did not indicate a higher fre-
quency of anemia in patients treated with simeprevir +
PegIFNα-2a + RBV, compared to PegIFNα-2a + RBV
alone. No historical comparisons were possible for cuta-
neous events such as rash and/or pruritus. Data from
RCTs in non-HIV patients on cutaneous events associated
with simeprevir are heterogeneous. While two studies re-
ported no differences between simeprevir and placebo
(PROMISE, QUEST-1), two other trials reported a higher
frequency of rash and photosensitivity (QUEST-2) or rash
(ASPIRE) in the simeprevir group.
Treatment recommendations for chronic hepatitis C
have changed dramatically during the last few years, based
on the availability of new direct acting antiviral agents
such as telaprevir, boceprevir, simeprevir, sofosbuvir, and
daclatasvir. According to current guidelines for the treat-
ment of patients with HCV-1/HIV coinfection published
by the American Association for the Study of Liver Dis-
eases (AASLD) [28], simeprevir + PegIFNα-2a + RBV is
recommended as an alternative regimen for treatment-
naïve or treatment experienced (prior PEG/RBV relapse)
HIV/HCV- coinfected patients with genotype 1 who are
eligible to receive IFN. The World Health Organization
(WHO) Guideline [29] mention PegIFNα-2a + RBV alone
or in combination with simeprevir, telaprevir or bocepre-
vir as potential treatment options; and the guideline of the
European Association for the Study of the Liver (EASL)
[30] recommends simeprevir + PegIFNα-2a + RBV as one
of the six treatment options for HCV-1 infected patients.
In contrast to earlier findings of lower SVR rates in HIV/
HCV- coinfected patients, treatment response to triple
therapy or new interferon-free regimens is now compar-
able to those observed in patients with HCV-monoinfection
[30].
For the historical comparison between simeprevir +
PegIFNα-2a + RBV and PegIFNα-2a + RBV alone, some
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methodological limitations have to be considered. One
major limitation is that every historical comparison is
subject to potential biases that do not exist for random-
ized head-to-head comparisons. The evidence from such
a comparison is thus always considered to be lower than
corresponding evidence from RCTs. Study designs and
study populations differed between study C212 and the
trials included for the historical comparison, as well as
among the historical studies. As a consequence, factors
associated with the study outcome that differed between
study C212 and the historical studies may have con-
founded the results. No trial was identified that exactly
matched the study design of study C212. Main differ-
ences were the duration of PegIFNα-2a + RBV treatment
and the daily dose of RBV. Because of anticipated drug-
drug interactions between commonly used HIV nucleo-
sides and ribavirin, initial trials investigated lower ribavirin
doses (600 mg starting dose in the ACTG trial [12],
800 mg in APRICOT [19]). Subsequent European studies
[16] showed markedly improved HCV cure rates after
using weight adapted ribavirin. This was, however, not
demonstrated in the controlled randomized trial which
investigated different ribavirin dosages [21], so that the ac-
tual influence of ribavirin dose on SVR rates remains un-
clear. In addition, random effects meta-analyses were used
to take into account between-study variation of results. As
no meta-regression analysis was performed, no conclu-
sions regarding the impact of potential confounding fac-
tors on the outcomes of interest could be made. However,
the superiority of simeprevir + PegIFNα-2a + RBV over
PegIFNα-2a + RBV alone was not only evident for the
comparison with the meta-analysis results, but also for all
but one possible comparisons with the individual studies
(excluding one study with N = 10 participants). In
addition, sensitivity analyses were performed for SVR24 in
which only trials with a treatment duration at least as long
as in study C212 and with the same weight-adapted RBV
dose were included. The results were very similar, indicat-
ing that these characteristics did not substantially bias the
historical comparison for the efficacy measure. Study
C212 included patients with previous PegIFNα-2a/RBV
treatment, while the historical trials did not or did not re-
port on that aspect. However, for SVR24 this was most
likely conservative with respect to the comparison of
simeprevir + PegIFNα-2a + RBV with PegIFNα-2a + RBV
alone, as SVR24 in study C212 was lower for patients with
previous PegIFNα-2a/RBV treatment than for treatment
naïve patients. Results regarding AEs from the historical
comparison have to be interpreted with special caution, as
differences in study design, treatment duration, and/or
HIV background therapy may have influenced the propor-
tion of patients with these events. It is difficult to conclude
in which direction (i.e. higher or lower risk) the effect
measures might were biased by the combination of these
study differences. The finding of a lower number of pa-
tients who interrupted treatment due to an AE with sime-
previr + PegIFNα-2a + RBV compared to PegIFNα-2a +
RBV alone was based on one historical study and should
be interpreted with caution.
However, the study also has important strengths. The
historical comparison was based on a systematic review
of available evidence for the treatment efficacy of
PegIFNα-2a + RBV in HCV-1/HIV coinfected patients.
Meta-analyses methods to combine the available
evidence were used instead of using a single study for a
historical comparison. The main results for SVR24 did
not depend on the type of meta-analysis model used
(fixed or random effects) and were stable in sensitivity
analyses that tended to underestimate the treatment dif-
ference between simeprevir + PegIFNα-2a + RBV and
PegIFNα-2a + RBV alone.
Conclusions
This historical comparison provides first systematic evi-
dence for the superiority of simeprevir + PegIFNα-2a +
RBV compared to PegIFNα-2a + RBV alone in patients
with HCV-1 and HIV coinfection. The absolute differ-
ence of the proportion of patients with SVR24 was
approx. 45 %, which is compatible with data from sime-
previr RCTs that included non-HIV patients with HCV-
1 infection. No increases in the frequency of important
AE categories were identified, however these analyses
were limited methodologically and by the low number of
studies contributing data to these comparisons. Add-
itional data (for instance from observational studies) on
the safety of simeprevir triple therapy compared to
PegIFNα-2a + RBV alone and compared to other HCV
treatment options would be desirable.
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